Sage Journals: Discover world-class research

Abstract

Background

The endogenous steroidal inhibitor of sodium–potassium-dependent adenosine triphosphate and natriuretic hormone, marinobufagenin, plays a physiological role in ionic homeostasis. Animal models suggest that elevated marinobufagenin adversely associates with cardiac and renal, structural and functional alterations. It remains uncertain whether marinobufagenin relates to the early stages of target organ damage development, especially in young adults without cardiovascular disease. We therefore explored whether elevated 24-hour urinary marinobufagenin excretion was related to indices of subclinical target organ damage in young healthy adults.

Design

This cross-sectional study included 711 participants from the African-PREDICT study (black 51%, men 42%, 24.8 ± 3.02 years).

Methods

We assessed cardiac geometry and function by two-dimensional echocardiography and pulse wave Doppler imaging. 24-Hour urinary marinobufagenin and sodium excretion were measured, and the estimated glomerular filtration rate determined.

Results

Across marinobufagenin excretion quartiles, left ventricular mass (P < 0.001), end diastolic volume (P < 0.001), stroke volume (P = 0.004) and sodium excretion (P < 0.001) were higher within the fourth compared with the first quartile. Partial regression analyses indicated that left ventricular mass (r = 0.08, P = 0.043), end diastolic volume (r = 0.10, P = 0.010) and stroke volume (r = 0.09, P = 0.022) were positively related to marinobufagenin excretion. In multivariate-adjusted regression analysis, left ventricular mass associated positively with marinobufagenin excretion only in the highest marinobufagenin excretion quartile (adjusted R²= 0.20; β = 0.15; P = 0.043). This relationship between left ventricular mass and marinobufagenin excretion was evident in women (adjusted R²= 0.06; β = 0.127; P = 0.015) but not in men (adjusted R²= 0.06; β = 0.007; P = 0.92).

Conclusions

Left ventricular mass positively and independently associates with marinobufagenin excretion in young healthy adults with excessively high marinobufagenin excretion. Women may be more sensitive to the effects of marinobufagenin on early structural cardiac changes.

Keywords

Apparently healthy left ventricular mass index marinobufagenin young adults

Get full access to this article

View all access options for this article.

References

Fedorova

Zernetkina

Shilova

et al.

Synthesis of an endogenous steroidal Na pump inhibitor marinobufagenin, implicated in human cardiovascular diseases, is initiated by CYP27A1 via bile acid pathway. Circ Cardiovasc Gene 2015; 8: 736–745.

Fedorova

Doris

Bagrov

. Endogenous marinobufagenin-like factor in acute plasma volume expansion. Clin Exp Hypertens 1998; 20: 581–591.

Strauss M, Smith W, Wei W, et al. Marinobufagenin is related to elevated central and 24 hr systolic blood pressures in young black women: the African-PREDICT study. Hypertens Res 2018; 41: 183–192.

Bagrov

Shapiro

Fedorova

. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 2009; 61: 9–38.

Elkareh

Kennedy

Yashaswi

et al.

Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 2007; 49: 215–224.

Elkareh

Periyasamy

Shidyak

et al.

Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy. Am J Physiol-Renal 2009; 296: F1219–F1226.

Kennedy

Shrestha

Sheehey

et al.

Elevated plasma marinobufagenin, an endogenous cardiotonic steroid, is associated with right ventricular dysfunction and nitrative stress in heart failure. Circ Heart Fail 2015; 8: 1068–1076.

Kennedy

Vetteth

Periyasamy

et al.

Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 2006; 47: 488–495.

Fedorova

Raju

El-Okdi

et al.

The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition. Am J Physiol-Renal 2009; 296: F922–F934.

10.

Tian

Haller

Periyasamy

et al.

Renal ischemia regulates marinobufagenin release in humans. Hypertension 2010; 56: 914–919.

11.

Uddin

Horvat

Demorrow

et al.

Marinobufagenin is an upstream modulator of Gadd45a stress signaling in preeclampsia. BBA 2011; 1812: 49–58.

12.

Puschett

Agunanne

Uddin

. Marinobufagenin, resibufogenin and preeclampsia. BBA 2010; 1802: 1246–1253.

13.

Fedorova

Talan

Agalakova

et al.

Coordinated shifts in Na/K-ATPase isoforms and their endogenous ligands during cardiac hypertrophy and failure in NaCl-sensitive hypertension. J Hypertens 2004; 22: 389–397.

14.

Kolmakova

Haller

Kennedy

et al.

Endogenous cardiotonic steroids in chronic renal failure. Nephrol Dial Transplant 2011; 26: 2912–2919.

15.

Swanepoel

Schutte

Cockeran

et al.

Sodium and potassium intake in South Africa: an evaluation of 24-hour urine collections in a white, black, and Indian population. J Am Soc Hypertens 2016; 10: 829–837.

16.

Mancia

Fagard

Narkiewicz

et al.

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–1357.

17.

Simera

Moher

Hoey

et al.

A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010; 40: 35–53.

18.

Nagueh

Smiseth

Appleton

et al.

Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016; 29: 277–314.

19.

Sahn

DeMaria

Kisslo

et al.

Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083.

20.

Lang

Badano

Mor-Avi

et al.

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imag 2015; 16: 233–271.

21.

de Simone

Devereux

Daniels

et al.

Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight. Circulation 1997; 95: 1837–1843.

22.

Teichholz

Kreulen

Herman

et al.

Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 1976; 37: 7–11.

23.

World Health Organization. Protocol for population level sodium determination in 24-h urine samples. Prepared by WHO/PAHO Regional Expert Group for Cardiovascular Disease Prevention through Population-wide Dietary Salt Reduction: Sub-Group for Research and Surveillance, 2010.

24.

Fedorova

Simbirtsev

Kolodkin

et al.

Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J Hypertens 2008; 26: 2414–2414.

25.

Levey

Stevens

Schmid

et al.

A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.

26.

Gotfried

Wiesen

Raina

et al.

Finding the cause of acute kidney injury: which index of fractional excretion is better?

Cleve Clin J Med 2012; 79: 121–126.

27.

Gaborit

Varro

Le Bouter

et al.

Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. J Mol Cell Cardiol 2010; 49: 639–646.

28.

Goel

Zhang

Anderson

et al.

Gender difference in rat aorta vasodilation after acute exposure to high glucose: involvement of protein kinase C β and superoxide but not of Rho Kinase. Cardiovasc Res 2007; 76: 351–360.

29.

Fedorova

Talan

Agalakova

et al.

Myocardial PKC β2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in dahl hypertension. Hypertension 2003; 41: 505–511.

30.

Obradovic

Stewart

Pitt

et al.

In vivo effects of 17beta-estradiol on cardiac Na(+)/K(+)-ATPase expression and activity in rat heart. Mol Cell Endocrinol 2014; 388: 58–68.

31.

Levy

Garrison

Savage

et al.

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566.

32.

Piepoli

Hoes

Agewall

et al.

2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016; 23: NP1–NP96.

33.

United Nations General Assembly. Political declaration of the high-level meeting of the general assembly on the prevention and control of non-communicable diseases, New York: United Nations, 2011.

34.

World Health Organization. Guideline: Sodium intake for adults and children, Geneva: World Health Organization, 2012.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.42 MB

Marinobufagenin and left ventricular mass in young adults: The African-PREDICT study

Abstract

Background

Design

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material